The New England journal of medicine, 2018-02, Vol.378 (5), p.449-459
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- Ist Teil von
- The New England journal of medicine, 2018-02, Vol.378 (5), p.449-459
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- CAR T cells expressing anti-CD19 and signaling molecules CD28 and CD3-zeta chain induced complete remission in 83% of patients with refractory ALL. Patients with a low disease burden had longer survival and a lower rate of toxic effects than those with a high disease burden.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1709919Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6637939
- Format
- –
- Schlagworte
- Acute lymphoblastic leukemia, Adult, Adults, Aged, Autografts, Binding sites, Bone marrow, Cancer, Cancer therapies, CD19 antigen, Chemotherapy, Chimeric antigen receptors, Clinical trials, Cytokines, Cytokines - metabolism, Follow-Up Studies, Humans, Leukemia, Lymphatic leukemia, Lymphocytes, Lymphocytes B, Lymphocytes T, Medical prognosis, Middle Aged, Multivariate analysis, Neurotoxicity, Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality, Receptors, Antigen, T-Cell - therapeutic use, Recurrence, Remission, Remission Induction, Survival Analysis, T-Lymphocytes - immunology, Tomography